Arthur Levinson has recruited an Amgen vet as Calico’s new head of development for everything in preclinical through Phase II development at Google’s buzzy anti-aging biotech.
Aarif Khakoo, who most recently headed a team of 100 investigators doing the translational work at Amgen, is headed over to Calico, which has its base in South San Francisco. His earlier work left him in charge of everything from first-in-human to proof-of-concept studies for cardiometabolic, inflammation, neuroscience and oncology, as well as clinical biomarkers, in vitro diagnostics, and digital health.
He’s headed to one of the most buzzed about biotechs with the lowest profile in biopharma. Calico has set its sights on developing new drugs that offer a better quality of life for a lengthy span — though we’ve heard little about their actual clinical plans. And he’s arriving a little over a year after Hal Barron left his job as president of R&D at Calico to take the top R&D post at GlaxoSmithKline.
Khakoo has a prestigious pedigree, with education at Columbia and Johns Hopkins as well as a stint at MD Anderson.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,900+ biopharma pros who read Endpoints News by email every day.Free Subscription